

Special Issue

Molecular Genetics of Breast and Ovary Cancer

Message from the Guest Editors

Dear Colleague, The discovery of the first two breast cancer genes, *BRCA1* and *BRCA2*, dates back to more than two decades. Since then, a number of high-to-moderate penetrance susceptibility genes were shown to impact on the lifetime risk for breast/ovarian cancer, many of them being involved in homologous recombination (HR). Also, genetic variations in low-penetrance susceptibility loci seem to affect breast/ovarian cancer predisposition or to contribute as genetic risk modifiers, through a polygenic inheritance model. However, clear guidelines to use this knowledge for risk-reducing purposes in mutation carriers is still lagging behind. *BRCA1/BRCA2* mutation status has recently become a predictive biomarker for the treatment of breast and ovarian cancer patients with PARP inhibitors. Additional genetic defects in HR and other DNA repair pathways may account for constitutional or acquired resistance/sensitivity to PARP inhibitors and other targeted therapy. For this Special Issue of *Cancers*, we will welcome manuscripts describing novel data, methods, collaborative initiatives, editorials, and reviews related to these topics.

Guest Editors

Prof. Giuseppe Giannini

Prof. Dr. Laura Ottini

Dr. Anna Coppa

Deadline for manuscript submissions

closed (31 October 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/27464

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)